WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



S. D. Rihana*, G. Sandhya Rani, G. Sumanjali, G. Jyothi, G. Chaitanya and D. Rama Brahma Reddy


Uveal melanoma (UM) is the most probable intraocular malignancy and arises from melanocytes in the iris, ciliary body, or choroid. primary diagnosis and local treatment is crucial, as survival corresponds with primary tumor size. However, approximately 50% of patients will develop metastatic pathological condition with 6–12 months’ survival from metastatic diagnosis. Genomic analyses have led to the advancement of gene-expression profiles that effectively forecast metastatic progression; unfortunately, no adjuvant therapy has been shown to prolong survival to date. New insights into the molecular biology of UM have discovered recurrent activating mutations in genes encoding for the G-protein α- subunit, GNAQ and GNA11, and improved understanding of the downstream signaling pathways MAPK, PI3K/Akt, and Hippo have managed an array of new targets for treatment of this disease. Studies are under way with rationally developed regimens targeting these pathways, and innovative agents are under development. We inspect the diagnosis, management, and surveillance of primary UM and the adjuvant therapy trials under way.

Keywords: uveal melanoma, ocular melanoma, GNAQ, GNA11, MAP kinase, MEK, metastasis.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More